Penumbra Amends Incorporation Certificate After Stockholder Vote

Penumbra ( (PEN) ) has provided an update.

On May 28, 2025, Penumbra, Inc. filed an Amended and Restated Certificate of Incorporation with the State of Delaware, following stockholder approval at its Annual Meeting. During the meeting, stockholders voted on several proposals, including the election of Class I directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation. Additionally, amendments to the company’s charter were approved to phase in board declassification and eliminate supermajority voting requirements, reflecting significant governance changes aimed at enhancing corporate flexibility and shareholder influence.

The most recent analyst rating on (PEN) stock is a Buy with a $232.00 price target. To see the full list of analyst forecasts on Penumbra stock, see the PEN Stock Forecast page.

Spark’s Take on PEN Stock

According to Spark, TipRanks’ AI Analyst, PEN is a Outperform.

Penumbra’s overall stock score reflects strong financial performance with notable revenue and margin growth, primarily driven by its U.S. thrombectomy business. However, the high P/E ratio suggests potential overvaluation, and short-term technical indicators point to possible weakness. The earnings call provided positive growth insights but also highlighted challenges in international markets. These factors collectively contribute to a balanced overall score.

To see Spark’s full report on PEN stock, click here.

More about Penumbra

Penumbra, Inc. operates in the medical device industry, focusing on innovative therapies for neuro and vascular conditions. The company is known for its development of products that address challenging medical conditions, with a market focus on improving patient outcomes through advanced technology.

Average Trading Volume: 513,199

Technical Sentiment Signal: Buy

Current Market Cap: $10.28B

See more insights into PEN stock on TipRanks’ Stock Analysis page.